Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for GRIFOLS SA

All Data per May 25, 2023

Industry:

Drug Manufacturers—General

Last Close:

11.35 EUR

Expected Dividend:

0.00 %

Payoffs per Year:

1
Business Summary
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Competitors View

Ordering

PFIZER

USA		 0.89 3.74%
4.36%		 6.07% 4.49% 1.0 0.61
-43.29%		 46.05 16.02% 48.64 1.0

ABBVIE

USA		 1.02 3.5%
4.3%		 10.17% 5.07% 1.0 3.15
-14.88%		 42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR		 1.06 3.6%
2.11%		 5.97% 4.3% 0.5 16.21
-3.86%		 67.14 17.71% 38.41 3.0

SANOFI

FRA		 1.11 3.8%
3.58%		 1.59% 3.73% 1.0 0.88
-12.18%		 49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN		 0.98 1.38%
2.08%		 16.13% 2.65% 1.0 3.06
-38.8%		 42.96 15.38% 77.21 5.0

MERCK & CO.

USA		 1.09 3.4%
2.67%		 5.29% 3.94% 1.0 3.67
-11.68%		 47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA		 0.95 2.6%
4.47%		 2.48% 2.66% 1.0 0.53
-24.44%		 34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN		 1.01 2.35%
2.85%		 19.78% 5.38% 1.0 1.47
-19.06%		 31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA		 1.1 2.36%
1.06%		 14.8% 4.25% 1.0 11.83
-12.71%		 45.05 7.83% 21.77 9.0

AMGEN

USA		 0.95 2.75%
3.93%		 10.11% 3.97% 1.0 1.83
-17.4%		 38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN		 1.07 2.05%
0.7%		 6.06% 2.46% 1.0 10.21
-17.26%		 41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN		 0.95 1.65%
1.91%		 8.0% 2.16% 1.0 3.07
-15.61%		 44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN		 1.01 2.16%
1.93%		 0.0% 1.98% 1.0 0.44
-14.62%		 29.23 12.66% 72.92 13.0

ROCHE

CHE		 0.92 3.1%
3.27%		 1.69% 3.06% 1.0 0.55
-23.37%		 40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA		 1.04 3.5%
3.89%		 3.61% 3.76% 0.5 0.24
-42.43%		 36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA		 0.96 2.69%
3.05%		 5.9% 3.2% 1.0 0.19
-12.62%		 46.37 -0.95% 40.99 16.0

BAYER

GER		 1.06 2.96%
3.68%		 0.81% 2.81% 0.5 -0.3
-58.76%		 37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR		 1.02 6.49%
2.62%		 0.0% 5.95% -1.0 0.02
-24.56%		 47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP
 0.91 1.1%
0.0%		 -53.18% 0.2% -0.5 -0.11
-65.73%		 32.66 2.01% 38.04 19.0

Information for GRIFOLS SA

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 0.00 11.35 0.00
2022 0.00 10.77 0.00
2021 0.36 16.88 2.16
2020 0.16 23.88 0.68
2019 0.35 31.43 1.10
2018 0.40 22.77 1.77
2017 0.32 24.42 1.29
2016 0.31 18.88 1.66

Fundamentals

Chart